About Project

Our goal is to treat cancers with novel combinations using our unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines & adjuvants

 

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today, the upcoming launch of its Biotech Electronic Security Token (BEST), the first digital security offering in healthcare.  Tokenization will enable qualified investors to directly invest in a single biotech product while preserving shareholder equity.

The growing adoption of blockchain technology, together with the latest financial regulatory changes, offers new alternatives to fund selected products with digital securities and opens an unprecedented opportunity to target financial investments in pharmaceutical product development.

Social Networks
Team

Main Team (10)

  • Garo Armen, PhD
    Chairman and CEO
  • Jennifer Buell, PhD
    Chief Operating Officer
  • Ozer Baysal
    Chief Commercial Officer
  • Julie DeSander
    Vice President, Business Development and Alliance Management
  • Anna Wijatyk, MD
    Vice President of Clinical Development
  • Sunil Gupta, MBBS, FRCPC
    Vice President of Regulatory & Pharmacovigilance
  • Alex Duncan, PhD
    Chief Technology Officer
  • Christian Cortis, PhD
    Chief Strategy Officer & Head of Finance
  • Evan Kearns, J.D.
    Vice President & General Counsel
  • Christine Klaskin
    Vice President, Finance & Principal Accounting Officer

Board of Directors (6)

  • Garo H. Armen, PhD
    Chairman and CEO
  • Brian Corvese
  • Wadih Jordan
  • Ulf Wiinberg
  • Timothy R. Wright
  • Allison Jeynes-Ellis

Advisors (4)

  • Robert Stein, MD, PhD
    Senior R&D Advisor
  • Hagop Youssoufian, MD
    Senior Clinical Strategist
  • Tyler Curiel, MD, MPH
    Senior Strategist for Translational and Biomarker Development
  • Mary K. Pendergast

Token Sale
  • Investment Goal
    $100M
  • Minimum Investment
    $0 USD
Asset Details
  • Token Holder Rights
    Dividends, Interest Right, Equity Ownership
  • Type of Security
    Debt Instrument
Token Holder Rights

BEST holders will benefit from downside protection provisions including a capital recall feature allowing them to reclaim a substantial portion of the original purchase price at any time following initial investment while retaining a stake in the security's upside that would result in a "make whole" outcome if the underlying project is successful.

 

An equity raise would be dilutive to all investors as it sells a portion of the of the entire company and its portfolio, whereas BEST provides investment in a specific product; hence providing existing investors full exposure to the rest of a company’s portfolio without the dilution typical of equity offerings.

BEST also provides BEST investors the ability to pick products of their interest for direct investment. For example, with our first BEST offering investors will have the opportunity to invest in our latest stage candidate (AGEN2034, our anti-PD-1 antibody).

Token Details
  • Ticker
    BEST
Company Profile
  • Legal Name
    Agenus Inc.
  • Country of Origin
    United States
  • Country of Incorporation
    United States
  • Registered Office
    3 Forbes Road, Lexington, MASSACHUSETTS, 02421
Regulation
  • Regulation
    US Securities and Exchange Commission - Reg D (506b, 506c)

You May Also Be Interested In